Adagene (ADAG) Receivables - Net (2019 - 2026)

Adagene (ADAG) posted quarterly Receivables - Net of $3.0 million for Q4 2021, up 384.51% quarter-over-quarter from $619185.0 in Q2 2021.

Adagene (ADAG) Receivables - Net (2019 - 2026) Analysis & Trends

Adagene (ADAG) has reported Receivables - Net for 2 consecutive years, with $3.0 million the latest figure, recorded in Q4 2021.

In Q4 2021, Receivables - Net changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2021 stood at $3.0 million (changed N/A YoY), while the FY2021 annual figure was $3.0 million, changed N/A from the prior year.
Receivables - Net advanced to $3.0 million in Q4 2021 per ADAG's latest filing, from $619185.0 in the prior quarter.
Across five years, Receivables - Net topped out at $3.0 million in Q4 2021 and bottomed at $480000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Adagene	310.54 Mn	310.54 Mn	-

Download Data